The RAS Inhibitor Daraxonrasib is Showing Encouraging New Results – Dana-Farber
oncodaily - Dana-Farber Cancer Institute shared a post on LinkedIn: “For years, RAS was considered one of the toughest targets in cancer research. In pancreatic cancer, that challenge is especially urgent. New […]
AI Summary: A targeted RAS inhibitor, daraxonrasib, produced promising clinical activity in patients with NRAS-mutant melanoma, demonstrating tumor responses and a tolerable safety profile in early studies. The data suggest a viable therapeutic avenue for a historically hard-to-treat subset and justify larger trials to confirm benefit — because apparently NRAS wasn’t going to cure itself.
Related Stories
Rogaratinib shows activity in SDH‑deficient GIST phase 2 trial / 7 wks
Genetic clues explain tagraxofusp resistance in rare leukemia (BPDCN) / 7 days
Adjuvant selpercatinib sharply cuts recurrence in RET‑fusion lung cancer / 6 wks
CRISPR CD33‑deleted allogeneic transplant shows early AML promise / 2 months
Single‑cycle pembrolizumab yields striking responses in dMMR colon cancer / 2 months
EMERALD‑3 tests tremelimumab/durvalumab combos for embolisation‑eligible HCC / 15 days
Long‑term Botensilimab+Balstilimab data show durable responses in MSS CRC / 21 days
StackHealth RSS
You can now follow topics by RSS - browse the complete list of topics, people, and organizations. Or, try Medicare Advantage (not listed), Mergers and Acquisitions, Food Safety, FDA and look for the RSS link.
StackHealth Time Machine